{
  "main_header": {
    "sid": 1003693,
    "name": "Dipna Pharmachem",
    "stock_name": "Dipna Pharmachem",
    "full_name": "Dipna Pharmachem Ltd",
    "name_url": "stocks-analysis/dipna-pharmachem",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "15.00",
    "chg": -0.99,
    "chgp": "-6.19%",
    "dir": -1,
    "prev_price": "15.99",
    "mcapval": "42.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 543594,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE0MC401013",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": 30000,
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/dipna-pharmachem-1003693-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "How has been the historical performance of Dipna Pharmachem?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-dipna-pharmachem-3732003",
        "imagepath": "",
        "date": "2025-11-26 22:51:04",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profitability Trends</strong></p>\n<p>Dipna Pharmachem's net sales have demonstrated considerable volatility. The company recorded a peak in the fiscal year ending March 2022 with net sales reaching ₹727.56 crores, a substantial increase from ₹31.00 crores in March 2021. However, this surge was not sustained, as sales declined sharply to ₹99.93 crores in March 2023, followed by a moderate recovery to ₹164.34 crores in March 2024, and then a drop to ₹124.92 crores in March 2025.</p>\n<p>Total operating income mirrored this pattern, with the highest figure in March 2022 at ₹727.56 crores, before settling to more modest levels in subsequent years. The company's expenditure profile shifted notably, with raw material costs being significant only in March 2022 (₹676.67 crores), while pur..."
      },
      {
        "title": "Is Dipna Pharmachem overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-dipna-pharmachem-overvalued-or-undervalued-3723729",
        "imagepath": "",
        "date": "2025-11-24 08:22:39",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Valuation Metrics and What They Indicate</strong></p>\n<p>Dipna Pharmachem’s price-to-earnings (PE) ratio stands at approximately 41.9, which is notably high compared to many of its pharmaceutical peers. A PE ratio at this level often suggests that investors are pricing in strong future growth expectations. However, the company’s return on capital employed (ROCE) and return on equity (ROE) are relatively modest at 6.2% and 2.5% respectively, indicating that current profitability does not fully justify the elevated valuation multiples.</p>\n<p>The price-to-book (P/B) ratio is close to 1.06, suggesting the stock is trading near its book value, which can be seen as a neutral signal. Meanwhile, enterprise value to EBITDA (EV/EBITDA) is around 16.6, which is moderate but still higher than some attr..."
      },
      {
        "title": "Why is Dipna Pharmachem falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-dipna-pharmachem-fallingrising-3722295",
        "imagepath": "",
        "date": "2025-11-22 01:28:41",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Intraday Price Movements and Volatility</strong></p>\n<p>Dipna Pharmachem's trading on 21-Nov was characterised by substantial volatility, with the stock swinging between an intraday low of ₹13.96 and a high of ₹17.06, representing a wide range of ₹3.10. The stock opened with a gap down of nearly 10%, signalling initial bearish sentiment. However, it recovered strongly during the session, ultimately closing with an 8.9% gain. This intraday rebound suggests active trading interest and a battle between buyers and sellers throughout the day.</p>\n<p>The weighted average price indicates that a larger volume of shares traded closer to the lower end of the price range, which may imply that despite the recovery, selling pressure was still present. Nevertheless, the stock outperformed its sector by 10..."
      },
      {
        "title": "When is the next results date for Dipna Pharmachem?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-dipna-pharmachem-3718957",
        "imagepath": "",
        "date": "2025-11-20 23:15:42",
        "description": "Dipna Pharmachem will declare its results on 26 November 2025...."
      },
      {
        "title": "How has been the historical performance of Dipna Pharmachem?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-dipna-pharmachem-3716266",
        "imagepath": "",
        "date": "2025-11-19 22:46:08",
        "description": "Answer:\nThe historical performance of Dipna Pharmachem shows significant fluctuations in its financial metrics over the years.\n\nBreakdown:\nDipna Pharmachem's net sales have varied considerably, peaking at 727.56 Cr in March 2022 before declining to 124.92 Cr in March 2025. The total operating income followed a similar trend, reaching 727.56 Cr in March 2022 and dropping to 124.93 Cr by March 2025. The company's total expenditure, excluding depreciation, also decreased from 705.56 Cr in March 2022 to 121.48 Cr in March 2025. Operating profit (PBDIT) saw a decline from 22.10 Cr in March 2022 to 3.45 Cr in March 2025, while profit before tax remained relatively stable at 1.42 Cr in March 2025, consistent with the previous year. Profit after tax showed a slight decrease from 1.09 Cr in March 2024 to 0.97 Cr in March 2025. The company's total liabilities were 132.38 Cr in March 2025, slightly down from 132.90 Cr..."
      },
      {
        "title": "Why is Dipna Pharmachem falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-dipna-pharmachem-fallingrising-3709413",
        "imagepath": "",
        "date": "2025-11-17 23:53:54",
        "description": "As of 17-Nov, Dipna Pharmachem Ltd is experiencing a decline in its stock price, currently at 18.23, which represents a decrease of 0.77 or 4.05%. The stock has been underperforming, having fallen consecutively for the last four days, resulting in an overall return of -8.39% over the past week. Additionally, it is trading below its moving averages across various time frames, indicating a bearish trend. Despite a significant increase in delivery volume, which rose by 309.52% against the 5-day average, the stock's performance today has underperformed its sector by 4.33%. There is no information available regarding positive or negative factors that could further explain the stock's recent movement.\n\nIn the broader market context, the stock's short-term performance has been notably weaker compared to the benchmark Sensex, which has gained 1.69% over the past week. While Dipna Pharmachem has shown strong year-to..."
      },
      {
        "title": "How has been the historical performance of Dipna Pharmachem?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-dipna-pharmachem-3704163",
        "imagepath": "",
        "date": "2025-11-15 00:27:22",
        "description": "Answer:\nThe historical performance of Dipna Pharmachem shows significant fluctuations in its financial metrics over the years.\n\nBreakdown:\nDipna Pharmachem's net sales have varied considerably, peaking at 727.56 Cr in Mar'22 before declining to 124.92 Cr in Mar'25. The total operating income followed a similar trend, reaching a high of 727.56 Cr in Mar'22 and dropping to 124.93 Cr in Mar'25. The company's operating profit (PBDIT) also saw a decline from 22.10 Cr in Mar'22 to 3.45 Cr in Mar'25, while the profit before tax remained relatively stable at 1.42 Cr in Mar'25, consistent with the previous year. Profit after tax showed a slight decrease from 1.09 Cr in Mar'24 to 0.97 Cr in Mar'25. On the balance sheet, total liabilities were 132.38 Cr in Mar'25, slightly down from 132.90 Cr in Mar'24, while total assets remained nearly unchanged at 132.38 Cr. The company reported a negative cash flow from operating ..."
      },
      {
        "title": "When is the next results date for Dipna Pharmachem?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-dipna-pharmachem-3691264",
        "imagepath": "",
        "date": "2025-11-11 23:20:35",
        "description": "Dipna Pharmachem is scheduled to declare its results on 14 November 2025...."
      },
      {
        "title": "Is Dipna Pharmachem overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-dipna-pharmachem-overvalued-or-undervalued-3687791",
        "imagepath": "",
        "date": "2025-11-11 08:14:01",
        "description": "As of 10 November 2025, Dipna Pharmachem's valuation grade has moved from very expensive to expensive. The company is currently considered overvalued. Key ratios include a PE ratio of 49.33, an EV to EBIT of 18.79, and a ROCE of 6.22%. \n\nIn comparison to its peers, Sun Pharma has a PE of 35.15 and an EV to EBITDA of 10.64, while Cipla, which is rated attractive, has a PE of 22.45 and an EV to EBITDA of 5.67. Despite a strong one-year stock return of 172.5% compared to the Sensex's 5.09%, the high valuation ratios suggest that Dipna Pharmachem may not be a prudent investment at its current price...."
      }
    ],
    "total": 91,
    "sid": "1003693",
    "stock_news_url": "https://www.marketsmojo.com/news/dipna-pharmachem-1003693"
  },
  "announcements": [
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. Saturday 29Th November 2025",
      "datetime": "29-Nov-2025",
      "details": "Board of Directors at its meeting held on today consider and allotted 2244000 Equity Shares pursuant to the conversion of warrants the 2244000 convertible warrants (out of a total 58032500 convertible warrants) to the allottee(s) belonging to the Non-promoter category.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Allotment",
      "datetime": "29-Nov-2025",
      "details": "Allotment of 2244000 Equity Shares pursuant to the conversion of 2244000 convertible warrants ( Out of a total 58032500 Convertible warrants) to the allottee(s) belonging to the Non-promoter category.",
      "source": "BSE"
    },
    {
      "caption": "Unaudited Financial Results For The Half Year Ended On 30Th September 2025.",
      "datetime": "26-Nov-2025",
      "details": "Unaudited Financial Results For the Half year ended on 30th September 2025.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Dipna Pharmachem Ltd has announced <strong>13:12</strong> rights issue, ex-date: 12 Feb 24",
          "dt": "2024-02-12",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

How has been the historical performance of Dipna Pharmachem?

2025-11-26 22:51:04

Revenue and Profitability Trends

Dipna Pharmachem's net sales have demonstrated considerable volatility. The company recorded a peak in the fiscal year ending March 2022 with net sales reaching ₹727.56 crores, a substantial increase from ₹31.00 crores in March 2021. However, this surge was not sustained, as sales declined sharply to ₹99.93 crores in March 2023, followed by a moderate recovery to ₹164.34 crores in March 2024, and then a drop to ₹124.92 crores in March 2025.

Total operating income mirrored this pattern, with the highest figure in March 2022 at ₹727.56 crores, before settling to more modest levels in subsequent years. The company's expenditure profile shifted notably, with raw material costs being significant only in March 2022 (₹676.67 crores), while pur...

Read More

Is Dipna Pharmachem overvalued or undervalued?

2025-11-24 08:22:39

Valuation Metrics and What They Indicate

Dipna Pharmachem’s price-to-earnings (PE) ratio stands at approximately 41.9, which is notably high compared to many of its pharmaceutical peers. A PE ratio at this level often suggests that investors are pricing in strong future growth expectations. However, the company’s return on capital employed (ROCE) and return on equity (ROE) are relatively modest at 6.2% and 2.5% respectively, indicating that current profitability does not fully justify the elevated valuation multiples.

The price-to-book (P/B) ratio is close to 1.06, suggesting the stock is trading near its book value, which can be seen as a neutral signal. Meanwhile, enterprise value to EBITDA (EV/EBITDA) is around 16.6, which is moderate but still higher than some attr...

Read More

Why is Dipna Pharmachem falling/rising?

2025-11-22 01:28:41

Intraday Price Movements and Volatility

Dipna Pharmachem's trading on 21-Nov was characterised by substantial volatility, with the stock swinging between an intraday low of ₹13.96 and a high of ₹17.06, representing a wide range of ₹3.10. The stock opened with a gap down of nearly 10%, signalling initial bearish sentiment. However, it recovered strongly during the session, ultimately closing with an 8.9% gain. This intraday rebound suggests active trading interest and a battle between buyers and sellers throughout the day.

The weighted average price indicates that a larger volume of shares traded closer to the lower end of the price range, which may imply that despite the recovery, selling pressure was still present. Nevertheless, the stock outperformed its sector by 10...

Read More

When is the next results date for Dipna Pharmachem?

2025-11-20 23:15:42

Dipna Pharmachem will declare its results on 26 November 2025....

Read More

How has been the historical performance of Dipna Pharmachem?

2025-11-19 22:46:08

Answer: The historical performance of Dipna Pharmachem shows significant fluctuations in its financial metrics over the years. Breakdown: Dipna Pharmachem's net sales have varied considerably, peaking at 727.56 Cr in March 2022 before declining to 124.92 Cr in March 2025. The total operating income followed a similar trend, reaching 727.56 Cr in March 2022 and dropping to 124.93 Cr by March 2025. The company's total expenditure, excluding depreciation, also decreased from 705.56 Cr in March 2022 to 121.48 Cr in March 2025. Operating profit (PBDIT) saw a decline from 22.10 Cr in March 2022 to 3.45 Cr in March 2025, while profit before tax remained relatively stable at 1.42 Cr in March 2025, consistent with the previous year. Profit after tax showed a slight decrease from 1.09 Cr in March 2024 to 0.97 Cr in March 2025. The company's total liabilities were 132.38 Cr in March 2025, slightly down from 132.90 Cr...

Read More

Why is Dipna Pharmachem falling/rising?

2025-11-17 23:53:54

As of 17-Nov, Dipna Pharmachem Ltd is experiencing a decline in its stock price, currently at 18.23, which represents a decrease of 0.77 or 4.05%. The stock has been underperforming, having fallen consecutively for the last four days, resulting in an overall return of -8.39% over the past week. Additionally, it is trading below its moving averages across various time frames, indicating a bearish trend. Despite a significant increase in delivery volume, which rose by 309.52% against the 5-day average, the stock's performance today has underperformed its sector by 4.33%. There is no information available regarding positive or negative factors that could further explain the stock's recent movement. In the broader market context, the stock's short-term performance has been notably weaker compared to the benchmark Sensex, which has gained 1.69% over the past week. While Dipna Pharmachem has shown strong year-to...

Read More

How has been the historical performance of Dipna Pharmachem?

2025-11-15 00:27:22

Answer: The historical performance of Dipna Pharmachem shows significant fluctuations in its financial metrics over the years. Breakdown: Dipna Pharmachem's net sales have varied considerably, peaking at 727.56 Cr in Mar'22 before declining to 124.92 Cr in Mar'25. The total operating income followed a similar trend, reaching a high of 727.56 Cr in Mar'22 and dropping to 124.93 Cr in Mar'25. The company's operating profit (PBDIT) also saw a decline from 22.10 Cr in Mar'22 to 3.45 Cr in Mar'25, while the profit before tax remained relatively stable at 1.42 Cr in Mar'25, consistent with the previous year. Profit after tax showed a slight decrease from 1.09 Cr in Mar'24 to 0.97 Cr in Mar'25. On the balance sheet, total liabilities were 132.38 Cr in Mar'25, slightly down from 132.90 Cr in Mar'24, while total assets remained nearly unchanged at 132.38 Cr. The company reported a negative cash flow from operating ...

Read More

When is the next results date for Dipna Pharmachem?

2025-11-11 23:20:35

Dipna Pharmachem is scheduled to declare its results on 14 November 2025....

Read More

Is Dipna Pharmachem overvalued or undervalued?

2025-11-11 08:14:01

As of 10 November 2025, Dipna Pharmachem's valuation grade has moved from very expensive to expensive. The company is currently considered overvalued. Key ratios include a PE ratio of 49.33, an EV to EBIT of 18.79, and a ROCE of 6.22%. In comparison to its peers, Sun Pharma has a PE of 35.15 and an EV to EBITDA of 10.64, while Cipla, which is rated attractive, has a PE of 22.45 and an EV to EBITDA of 5.67. Despite a strong one-year stock return of 172.5% compared to the Sensex's 5.09%, the high valuation ratios suggest that Dipna Pharmachem may not be a prudent investment at its current price....

Read More

View All News